Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2− metastatic breast cancer

Gebra Cuyun Cartera Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]

Kristin M. Sheffielda Eli Lilly and Company, Indianapolis, IN, USA

Anala Gossaib Flatiron Health, Inc., New York, NY, USA

Yu-Jing Huanga Eli Lilly and Company, Indianapolis, IN, USA

Yajun Emily Zhua Eli Lilly and Company, Indianapolis, IN, USA

Lee Bowmana Eli Lilly and Company, Indianapolis, IN, USA

Emily Nash Smytha Eli Lilly and Company, Indianapolis, IN, USA

Raina Mathurb Flatiron Health, Inc., New York, NY, USA

Aaron B. Cohenb Flatiron Health, Inc., New York, NY, USA;c School of Medicine, New York University, New York, NY, USA

Erik Rasmussenb Flatiron Health, Inc., New York, NY, USA

Shreya Balakrishnab Flatiron Health, Inc., New York, NY, USA

Claudia Morato Guimaraesa Eli Lilly and Company, Indianapolis, IN, USA

Sarah Rybowskia Eli Lilly and Company, Indianapolis, IN, USA

Andrew D. Seidmand Memorial Sloan Kettering Cancer Center, New York, NY, USA

Your download is now in progress and you may close this window